Physician profile
Daniel Kwan Dea
NPI 1013005503
$82,679.56
in general payments reported to CMS, 2019-2025
35 companies · $3,138 in 2025
The $3,138 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $7,375 · 2021: $12K · 2022: $19K · 2023: $16K · 2024: $2,827 · 2025: $3,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $8,559 · Consulting Fee: $400 · Education: $184 · Travel and Lodging: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,000.00 |
| Food and Beverage | $8,559.17 |
| Consulting Fee | $400.00 |
| Education | $183.98 |
| Travel and Lodging | $128.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $67,905.34 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals Lp | $4,036.24 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $2,033.84 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,332.13 | 2019-2025 | Ofev, Jascayd |
| Pfizer INC. | $816.81 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $748.93 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Insmed, INC. | $690.46 | 2020-2025 | Arikayce |
| Janssen Pharmaceuticals, INC | $661.45 | 2019-2024 | Xarelto |
| Viiv Healthcare Company | $600.00 | 2019 | |
| Genzyme Corporation | $547.56 | 2019-2025 | |
| Baxter Healthcare | $434.91 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Advanced Respiratory, INC | $394.09 | 2019-2021 | |
| Amgen INC. | $352.31 | 2023-2025 | Tezspire |
| Mylan Specialty L.P. | $306.67 | 2019-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $248.87 | 2019-2023 | Eliquis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $206.83 | 2024-2025 | Winrevair |
| Verona Pharma, INC. | $187.86 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $186.17 | 2019-2025 | Tyvaso, Tyvaso |
| Boston Scientific Corporation | $143.92 | 2025 | Farapulse |
| Shockwave Medical, INC | $125.89 | 2025 | |
| Gilead Sciences, INC. | $102.99 | 2019-2022 | |
| Stryker Corporation | $98.72 | 2024 | Prevalon |
| Viatris Specialty LLC | $89.59 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $84.99 | 2024 | |
| Ani Pharmaceuticals, INC. | $53.74 | 2024-2025 | Purified Cortrophin Gel |
| Pulmonx Corporation | $51.86 | 2022-2023 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Teva Pharmaceuticals USA, INC. | $50.76 | 2021 | |
| Novartis Pharmaceuticals Corporation | $49.19 | 2023-2024 | |
| Phadia US INC. | $39.78 | 2021-2024 | Immunocap |
| Sun Pharmaceutical Industries INC. | $19.28 | 2019 | |
| Abbvie INC. | $19.07 | 2023 | Avycaz |
| Regeneron Healthcare Solutions, INC. | $17.52 | 2019 | |
| Acadia Pharmaceuticals INC | $17.20 | 2022 | |
| Electromed, INC. | $12.59 | 2022 | |
| Philips North America LLC | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.